ESRRA and prostate carcinoma: ERRα represents a promising metabolic vulnerability in prostate cancer and PCSCs, and targeting mitochondrial metabolism in PCSCs through inhibition of ERRα provides a novel paradigm for developing more effective therapeutic strategies for advanced prostate cancer.